Your browser doesn't support javascript.
loading
Structural insights into the inhibition of glycine reuptake.
Shahsavar, Azadeh; Stohler, Peter; Bourenkov, Gleb; Zimmermann, Iwan; Siegrist, Martin; Guba, Wolfgang; Pinard, Emmanuel; Sinning, Steffen; Seeger, Markus A; Schneider, Thomas R; Dawson, Roger J P; Nissen, Poul.
Afiliação
  • Shahsavar A; Danish Research Institute of Translational Neuroscience-DANDRITE, Nordic EMBL Partnership for Molecular Medicine, Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
  • Stohler P; European Molecular Biology Laboratory, Hamburg Unit c/o DESY, Hamburg, Germany.
  • Bourenkov G; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
  • Zimmermann I; European Molecular Biology Laboratory, Hamburg Unit c/o DESY, Hamburg, Germany.
  • Siegrist M; Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
  • Guba W; Linkster Therapeutics AG, Zurich, Switzerland.
  • Pinard E; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
  • Sinning S; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
  • Seeger MA; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
  • Schneider TR; Department of Forensic Medicine, Aarhus University, Aarhus, Denmark.
  • Dawson RJP; Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
  • Nissen P; European Molecular Biology Laboratory, Hamburg Unit c/o DESY, Hamburg, Germany. thomas.schneider@embl-hamburg.de.
Nature ; 591(7851): 677-681, 2021 03.
Article em En | MEDLINE | ID: mdl-33658720
ABSTRACT
The human glycine transporter 1 (GlyT1) regulates glycine-mediated neuronal excitation and inhibition through the sodium- and chloride-dependent reuptake of glycine1-3. Inhibition of GlyT1 prolongs neurotransmitter signalling, and has long been a key strategy in the development of therapies for a broad range of disorders of the central nervous system, including schizophrenia and cognitive impairments4. Here, using a synthetic single-domain antibody (sybody) and serial synchrotron crystallography, we have determined the structure of GlyT1 in complex with a benzoylpiperazine chemotype inhibitor at 3.4 Å resolution. We find that the inhibitor locks GlyT1 in an inward-open conformation and binds at the intracellular gate of the release pathway, overlapping with the glycine-release site. The inhibitor is likely to reach GlyT1 from the cytoplasmic leaflet of the plasma membrane. Our results define the mechanism of inhibition and enable the rational design of new, clinically efficacious GlyT1 inhibitors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas da Membrana Plasmática de Transporte de Glicina / Glicina Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas da Membrana Plasmática de Transporte de Glicina / Glicina Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article